Skip navigation links
print | view as pdf | share

Omega-3 Fatty Acids, Diabetes and Cardiovascular Risk, An International Workshop


Omega-3 Fatty Acids, Diabetes and Cardiovascular Risk
An International Workshop

Organized by: Mid America Heart Institute of Saint Luke's Hospital
University of Missouri-Kansas City School of Medicine
&
Omega-3 Research Institute, Inc.

Co-Sponsored by: National Heart, Lung and Blood Institute
Office of Dietary Supplements
&
National Institute of Diabetes and Digestive and Kidney Diseases, NIH


November 30-December 2, 2000
Bethesda, MD

Agenda and Abstracts

Thursday

November 30, 2000
Introductory Session

19:00

20:00

Reception

How Do We Die -- Markers or Mediators? William Lands, PhD

20:30 Diabetes in Native Americans: Dietary Approaches to Reducing CVD Risk
Sven Ebbesson, PhD
21:00 The GISSI Prevention Study: Principal Findings
Roberto Marchioli, MD

Friday

December 1, 2000 

8:00 Welcome
William Harris, PhD

Session 1: Omega-3 FAs and CV Events in Diabetic Patients:  Clinical Trial and Epidemiologic Evidence
Chairs: Roberto Marchioli, MD and David Siscovick, MD

8:10

 

Effects of w3 FAs in Diabetic Patients in the GISSI Prevention Study
Roberto Marchioli, MD
8:30 Epidemiologic Evidence for a Protective Effect of Fish in Diabetic Patients
Martha Daviglus, MD, PhD
8:50

 

Prevention of Sudden Death By Low Intakes of w3 FAs
David Siscovick, MD
9:10 Discussion and Questions
Session Chairs

Session 2: Diabetes and CV Disease:  Magnification of Risk 
Chairs: Steven Haffner, MD and James O-Keefe, MD

9:30

 

Diabetes As a Risk Factor for CHD
Steven Haffner, MD
9:50 Diabetes, Lipoproteins, and Atherosclerosis
Henry Ginsberg, MD
10:10 Break
10:30

 

Hemostatic Abnormalities in Type 2 Diabetes
Norberta Schoene, PhD
10:50

 

Alterations in Blood Pressure and Endothelial Function in Types 2 Diabetes
James Sowers, MD
11:10

 

Diabetes and Autonomic Dysfunction: a Cause for Increased CHD Risk?
James O'Keefe, MD
11:30 Discussion and Questions
Session Chairs
11:45 Lunch

Session 3: Effects of w3 FAs on Insulin and Glucose Metabolism: Basic Science  
Chairs: Leonard Storlien, PhD and John Miles, MD

12:40 Fundamentals of Carbohydrate and Lipid Metabolism in Diabetes
John Miles, MD
13:00 Insulin Resistance and w3 FAs: Animal and Cell Culture
Michael Clandinin, PhD
13:20 Insulin Resistance and w3 FAs: Human
William L. Isley, MD
13:40 w3 FAs and Expression of Genes of Lipid Metabolism 
James Ntambi, PhD  
14:00 PPAR, SREBP and w3 FAs 
Donald Jump, PhD  
14:20 Discussion and Break
Session 4: Effects of w3 FAs on Insulin and Glucose Metabolism: Safety Issues  
Chair: William Connor, MD
15:00 Historical Concerns Regarding the Use of w3 FAs in Diabetic Patients 
Bengt Vessby, MD 
15:20 Multicenter Trial of w3 Fatty Acids in Type 2 Diabetic Patients 
Angela Rivellese, MD 
15:40 Diabetic Control is Not Adversely Affected by w3 FA Supplementation 
William Connor, MD 
16:00 Glycemic Control and Marine w3 FAs: A Meta-Analysis 
Mark Deeg, MD 
16:20 Discussion and Questions
Session Chairs
Session 5: Effects of w3 FAs on Risk Factors for CV Disease: Vascular Biology and Blood Pressure  
Chairs: Christine Ballantyne, MD and Clemens von Schacky, MD
16:40 Circulating Adhesion Molecules and w3 FAs 
Christine Ballantyne, MD
 
17:00 Effects of w3 FAs on Blood Pressure 
Trevor Mori, PhD
 
17:20 Fish Oils and Blood Pressure in Diabetic Patients 
Ingrid Toft, MD, PhD
17:40 Discussion and Questions
18:00 Adjourn
19:00 Conference Dinner and Special Program

Saturday

December 2, 2000 

 

07:00 Breakfast
  Session 5 (continued): Effects of w3 FAs on Risk Factors for CV Disease: Vascular Biology and Blood Pressure  
Chairs: Christine Ballantyne, MD and Clemens von Schacky, MD
08:00 Modulation of Endothelial Health by w3 FAs 
Gary McVeigh, MD 
08:20 Diminishing Inflammatory Responses With w3 FAs 
Clemens von Schacky, MD 
08:40 Discussion and Questions
Session Chairs
Session 6: Effects of w3 FAs on Risk Factors for CV Disease: Lipoprotein Metabolism and Platelet Function 
Chairs: Ernst Schaefer, MD and Howard Knapp, MD, PhD
08:50 High Fish Diets and Remnant Lipoprotein 
Ernst Schaefer, MD
09:10 Effects of w3 FAs on LDL-Cholesterol in Diabetes 
William Harris, PhD
09:30 Omega-3 Fatty Acids in the Treatment of the Atherogenic Lipoprotein Phenotype 
Christine Williams, PhD
09:50 Break
10:10 Omega-3 Fatty Acids and Statins: Combined Therapy for Dyslipidemia 
Arne Nordoy, MD
10:30 Overview of the w3 FAs, Hemostasis and Diabetes 
Howard Knapp, MD, PhD
10:50 Discussion and Questions
Session Chairs
Session 7: Effects of w3 FAs on Excitable Membranes: Implications for Diabetes 
Chair: Alexander Leaf, MD
11:10 Can w3 FAs Improve Heart Rate Variability? 
Erik Berg Schmidt, MD 
11:30 Omega-3 Fatty Acids and Arrhythmias: Animal Studies 
Peter McLennan, PhD
11:50 Altering Metabolic Function of Excitable Tissues With w3 FAs 
Alexander Leaf, MD 
12:10 Discussion and Questions
12:30 Lunch
Session 8: Nutritional Issues  
Chair: Artemis Simopoulos, MD
13:20 Evolutionary aspects of w3 FA intake
Artemis Simopoulos, MD
13:40 Incorporating w3 FAs into diabetic diets 
Sonja Connor, MS, RD 
Summary, Conclusions and Recommendations  
Chairs: William Harris, John Miles, James O'Keefe, Artemis Simopoulos, Robert Katz
14:00 Group Discussion of the following questions (addressed in working lunches)
  • Does it appear likely that up to 3 g of w3 FAs will materially reduce CVD risk in diabetes?
  • Are there significant safety concerns regarding the use of up to 3 g  of w3 FAs/day in patients with type 2 diabetes?
  • Is it time for a major clinical trial to test the hypothesis that w3 fatty acids can reduce CV events in patients with type 2 diabetes?

         € If yes, how should it be designed?

         € If no, what additional studies are 

            needed?  

        

 

 

15:30 Closing Remarks